Related Experiment Videos
Phase I study of pyrazofurin in refractory acute myelogenous leukemia
Abstract:
Pyrazofurin was administered to 17 patients with refractory acute myelogenous leukemia in 5-day courses every 2-3 weeks. Doses ranged from 30 to 60 mg/m2/day. Severe stomatitis and dermatitis occurred at doses effective in reducing the leukocyte count (45 mg/m2). Reduction of the dose to 30 mg/m2 resulted in less toxicity and less chemotherapeutic effect. These results indicate that at tolerable doses given as described, pyrazofurin had little antileukemic activity in acute myeologenous leukemia.
Insights
Pyrazofurin showed limited effectiveness against acute myelogenous leukemia in patients. Doses that reduced white blood cells caused severe side effects, while lower doses were less toxic but also less effective.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Acute myelogenous leukemia (AML) is a challenging hematologic malignancy.
- Refractory AML cases require novel therapeutic strategies.
- Pyrazofurin is an investigational antineoplastic agent.
Purpose of the Study:
- To evaluate the efficacy and toxicity of pyrazofurin in patients with refractory acute myelogenous leukemia.
- To determine the optimal dose of pyrazofurin for AML treatment.
Main Methods:
- A phase II clinical trial was conducted.
- 17 patients with refractory AML received pyrazofurin.
- Treatment involved 5-day courses at doses from 30 to 60 mg/m²/day every 2-3 weeks.
Main Results:
- Severe stomatitis and dermatitis were observed at 45 mg/m²/day, a dose effective in reducing leukocyte count.
- A reduced dose of 30 mg/m²/day led to decreased toxicity but also diminished chemotherapeutic effect.
- Pyrazofurin demonstrated minimal antileukemic activity at tolerable doses.
Conclusions:
- Pyrazofurin exhibits limited efficacy in treating acute myelogenous leukemia.
- The therapeutic window for pyrazofurin in AML appears narrow due to dose-limiting toxicities.